Open company graph database — free web & API
Login

Regimmune Corporation

株式会社レグイミューンREGiMMUNEAliasREGiMMUNE CorporationAlias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
5
§01

Basic information

BASIC
Head office
未記載
Chief executive
Dr. Steven Yang
Capital
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

4
Creating innovative immunotherapies for rare diseases and cancerRGI-2001, a synthetic small molecule formulated with liposome technology to treat GvHDDeveloping antibody therapeutic approaches that specifically target Tregs and reduce their undesiredDeveloping additional antibody drug candidates for immuno-oncology combination therapies
§04

Related companies

5 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
三福生醫
Alliance
輝瑞
Alliance
TPEx
regimmune.com
瑞格國際生技股份有限公司
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

17 EVENTS

Establishment of Japan's RyugeiSources

Signed licensing agreement with Japan's RikenSources

Reorganized and registered as a Taiwan companySources

Establishment of Ryugei in the United States, initiating preclinical trialsSources

Initiated Phase 2 clinical trial of RGI-2001Sources

RGI-2001 Haplo Peripheral Blood Sct phase 1 study startedSources

Initiated Phase 1 trial of RGI-2001 half-haploidentical peripheral blood stem cell transplantationSources

Licensed the commercial rights of RGI-2001 in Asia (excluding Japan) to BPC.Sources

Licensed commercial rights of RGI-2001 in Asia (excluding Japan) to Sanfu BiomedicalSources

Presented the final results of the RGI-2001 Phase 2b clinical trial at the ASTCT Annual Meeting.Sources

Presented final results of Phase 2b clinical trial of RGI-2001 at the ASTCT annual meetingSources

Presented the latest analytical findings from the RGI-2001 Phase 2b clinical trial at the AACR Annual Meeting.Sources

Presented latest analysis data of Phase 2b clinical trial of RGI-2001 at the AACR annual meetingSources

Published the results of the RGI-2001 Phase 2b clinical trial in Blood, the world’s leading journal in hematology.Sources

Presented antibody drug development results at "Antibody Engineering & Therapeutics Asia 2025" in Kyoto, JapanSources

Phase 2b clinical trial results of RGI-2001 published in the globally influential hematology journal "Blood"Sources

Presented antibody drug development findings at Antibody Engineering & Therapeutics Asia 2025 in Kyoto, Japan.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information8010001193784
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社レグイミューン
Trade name (kana)
レグイミューン
Name in English
Corporation type
301
Address
〒150-0022 東京都渋谷区恵比寿南3丁目1番1号
Postal code
1500022
Prefecture code
13
City code
113
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2018-08-06
Update date
2025-05-08
Change date
2025-05-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2322018
METI gBizINFO8010001193784
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8010001193784
Trade name
株式会社レグイミューン
Trade name (kana)
レグイミューン
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都渋谷区恵比寿南3丁目1番1号
Postal code
1500022
Prefecture
東京都
Prefecture code
13
City or district
渋谷区
City code
113
Street address
恵比寿南3丁目1番1号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2025-05-08
Key information
8010001193784
§09

Sources & updates

SOURCES
↑